GlaxoSmithKline has announced an alliance with Binnopharm, which will allow for the secondary manufacture of a number of GlaxoSmithKline vaccines in Russia.
The agreement will see GlaxoSmithKline supply bulk vaccine and provide technology and expertise to Binnopharm.
Binnopharm will undertake filling and packaging of a number of innovative GlaxoSmithKline vaccines, and be responsible for gaining approval for a supply of GlaxoSmithKline cervical cancer, rotavirus and pneumococcal vaccines under Binnopharm’s trademark for the Russian public market.
Local manufacture of these vaccines is expected to help Russia modernise its national immunisation calendar, adding additional vaccinations against highly prevalent infections including human papillomavirus (HPV), rotavirus and Streptococcus pneumoniae.
Financial details of the agreement have not been disclosed.